Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 03, 2015 10:32 AM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

212 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 44
Total Annual Compensation: $332.4K
Chief Financial Officer and Principal Accounting Officer
Age: 56
Total Annual Compensation: $202.8K
Chief Operating Officer and Senior Vice President
Age: 52
Total Annual Compensation: $290.2K
Vice President of Sales
Age: 44
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Announces Board Appointments

Intersect ENT, Inc. announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company's board of directors. Mr. Gallahue will serve as lead director and a member of the audit committee and Mr. Vernon will serve as chair of the nominating and corporate governance committee. Additionally, current director Casper de Clerq from Norwest Venture Partners has informed the board of directors that he will not seek re-election at the annual stockholder meeting in June. Kieran Gallahue most recently served as chairman and CEO of CareFusion. Tony Vernon recently retired as CEO of Kraft Foods Group, Inc.

Intersect ENT, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Intersect ENT, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. Revenue for the three months ended December 31, 2014 increased by 93% to $13.4 million from $7.0 million in the same period in 2013. This increase is attributable to higher unit sales via the acquisition of new accounts and driving adoption with existing customers. Net loss for the fourth quarter of 2014 improved to $3.7 million compared to $4.6 million for the fourth quarter of 2013. Fourth quarter basic and diluted LPS were $0.16 a share against $2.64 a year ago. Loss from operations was $3.686 million against $4.445 million a year ago. Revenue for the year ended December 31, 2014 increased by 115% to $38.6 million from $17.9 million in the same period in 2013. This increase is attributable to higher unit sales via acquisition of new accounts and expanded adoption by existing customers, and was supported by expansion of the company’s sales force. Net loss for the year was consistent with the prior year, with a net loss of $18.4 million for each of the years 2014 and 2013. Basic and diluted LPS for 2014 were $1.61 against $12.57 a year ago. Loss from operations was $18.078 million against $17.966 million a year ago.

Intersect ENT, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM

Intersect ENT, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

Similar Private Companies By Industry

Company Name Region
Pegasus Laboratories, Inc. United States
Fleming and Company Pharamceuticals, Inc. United States
Takeda Pharmaceuticals U.S.A., Inc. United States
Ardent Pharmaceuticals, Inc. United States
Psyadon Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.